Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GlucaTex is a brand name for glucagon, a recombinant hormone used as a critical emergency medication to treat severe hypoglycemia (dangerously low blood sugar) in patients with diabetes. It is also utilized in clinical settings to temporarily inhibit gastrointestinal motility during radiologic examinations. Glucagon is a 29-amino acid polypeptide produced via recombinant DNA technology that mimics the endogenous hormone secreted by the alpha cells of the pancreas. Its primary mechanism involves acting as an agonist at the glucagon receptor, predominantly in the liver, which triggers the activation of adenylate cyclase and increases intracellular cAMP levels. This signaling cascade promotes glycogenolysis (the breakdown of glycogen into glucose) and gluconeogenesis, leading to a rapid elevation of blood glucose levels. GlucaTex is typically supplied as a lyophilized powder in a kit for reconstitution and administration via intramuscular, subcutaneous, or intravenous injection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GlucaTex.